Intel Preps Internet TV Service and 3 Dow Movers for Today

Intel Corporation (NASDAQ:INTC): Current price $21.13

Intel’s media group has been recruiting new employees as it preps the launch of an Internet TV service later in 2013, says Reuters. The group wants to add 60 persons to its staff of more than 300, and that umber could hit 400 within the next six months, versus fewer than 100 a year ago.

Dow 15,000? S&P 1,600? Searching for market direction? Reduce information clutter and uncover key insights and investment ideas. Click here for Your Stock Investor Cheat Sheet Now!

intcc

Johnson & Johnson (NYSE:JNJ): Current price $78.72

The company’s subsidiary Cordis Corporation has finalized its purchase of Flexible Stenting Solutions, which develops innovative flexible peripheral arterial, venous, and biliary stents. Burrill & Company’s Burrill Capital Fund IV is presently an investor in Flexible Stenting Solutions. Financials of the transaction were not disclosed.

Dow 15,000? S&P 1,600? Searching for market direction? Reduce information clutter and uncover key insights and investment ideas. Click here for Your Stock Investor Cheat Sheet Now!

jnj

Microsoft Corporation (NASDAQ:MSFT): Current price $28.06

Back in 2010, Microsoft broke sales records when it debuted its Kinect, which is a movement-tracking device that permitted Xbox users to play their favorite games through gestures alone, with no need of a controller. Now, with the assistance from outside developers, the firm hopes to move the Kinect beyond gaming, says The Wall Street Journal. To begin, it’s expanding into China with a company-funded incubator program for outside developers to build products based on Kinect tech for an array of industries among which include health care and retail.

Dow 15,000? S&P 1,600? Searching for market direction? Reduce information clutter and uncover key insights and investment ideas. Click here for Your Stock Investor Cheat Sheet Now!

msft

Pfizer (NYSE:PFE): Current price $27.94

United States Senate members are starting to look into whether pharmaceutical firms should allow the government a larger return on its investment in drugs developed as a result of collaboration between the government and companies, reports The New York Times. Senator Ron Wyden (D-OR) is asking the National Institutes of Health to outline what the public will receive in return for its investment in the anti-arthritis drug Xeljanz, which was jointly developed by Pfizer and NIH.

Dow 15,000? S&P 1,600? Searching for market direction? Reduce information clutter and uncover key insights and investment ideas. Click here for Your Stock Investor Cheat Sheet Now!

pfe

Don’t Miss: Which Tech Players Rule the Internet?